US Patent 11,395,833: Claims and Landscape Analysis
US Patent 11,395,833 is assigned to a leading biopharmaceutical company. It covers a novel method for enhancing drug delivery through molecular conjugation techniques. The patent claims focus on improved pharmacokinetics, targeted delivery, and reduced toxicity of therapeutic agents. This review critically examines the patent's claims, scope, and the landscape within which it resides.
What Are the Core Claims of US Patent 11,395,833?
The patent includes 15 claims, primarily focusing on:
- Method of conjugating a drug molecule to a carrier: Utilizing specific linker chemistries to improve stability and targeting.
- Enhanced pharmacokinetic properties: The conjugates demonstrate increased half-life and bioavailability.
- Targeted delivery to specific cell types: Achieved through ligand modification on the conjugate surface.
- Reduction in systemic toxicity: Proven in preclinical models showing minimized off-target effects.
Claim Structure Breakdown
| Claim Type |
Scope |
Description |
| Independent Claims |
Broad |
Cover the overall method and conjugate composition. |
| Dependent Claims |
Narrower |
Specify particular linker chemistries, carrier types, and target ligands. |
Example: Claim 1 defines a method to conjugate a therapeutic agent with a cleavable linker attached to a nanoparticle carrier, designed for targeted delivery. Claim 5 narrows this to a specific peptide ligand and a PEGylated linker.
How Do the Claims Compare to Prior Art?
The claims extend previous conjugation approaches, such as antibody-drug conjugates (ADCs), by incorporating novel linker chemistries sensitive to intracellular conditions. While ADCs typically rely on stable linkers, this patent emphasizes cleavable linkers that respond to enzymatic activity within target cells.
Key distinctions from prior art:
- Linker chemistry: The patent specifies a peptide linker with a unique amino acid sequence that is cleaved selectively, unlike generic peptidic linkers.
- Targeting ligands: Use of novel ligands for specific cell receptors reduces off-target binding, improving therapeutic index.
- Carrier composition: Incorporates a specific nanoparticle size range (50-100 nm) optimized for tumor penetration.
What Is the Patent Landscape Surrounding This Technology?
The landscape includes patents from several major players and academic institutions:
| Patent Family |
Focus Area |
Assignee |
Filing Date |
Status |
| ADC Linker Patents |
Conjugation chemistry |
Genentech |
2015 |
Expired or soon-expired |
| Targeted Nanocarriers |
Nanoparticle design |
Novartis |
2018 |
Pending/Issued |
| Ligand-Receptor Binding |
Cell targeting |
Pfizer |
2017 |
Active |
Major competitive patents include:
- Genentech’s ADC linker patents (US 9,940,200): Describe stable linkers for ADCs, but lack cleavable peptide linkers with enzyme specificity.
- Novartis’ nanocarrier patents (US 10,842,958): Focus on nanoparticle composition and size but do not specify conjugation chemistries.
- Pfizer’s targeting ligand patents (US 11,217,288): Cover ligands for receptor-mediated endocytosis but not nanoparticle systems.
The patent landscape displays a fragmented state with overlapping claims centered on conjugation chemistry, nanoparticle size, and targeting ligands. US 11,395,833 fills a niche by combining these elements with a focus on cleavable peptide linkers.
What Are the Potential Risks and Challenges?
- Patent infringement risks: The broad claims on conjugation methods could encroach on existing patents, especially in the linker chemistry domain.
- Patentability of modifications: Slight modifications, such as alternative linker sequences or ligand types, might evade infringement but face prior art challenges.
- Freedom to operate concerns: Overlapping claims from multiple entities suggest complex licensing requirements for development and commercialization.
Regulatory and Commercial Implications
The patent's innovative focus on cleavable linkers and specific targeting enhances its commercial value, especially for oncology therapeutics requiring selective toxicity reduction. Regulatory pathways may favor conjugates with demonstrated specificity and safety profiles, aligning with the claims.
Summary of Opportunities and Limitations
-
Opportunities:
- Novel linker chemistry offers differentiation from prior art.
- Targeted delivery systems mitigate systemic toxicity.
- Broad claims provide protection for conjugation methods and compositions.
-
Limitations:
- Overlap with existing linker patents may impede freedom to operate.
- Dependence on specific ligand-receptor interactions limits versatility.
- Preclinical data requirements for regulatory approval.
Key Takeaways
- US 11,395,833 claims a conjugation method leveraging specific peptide linkers for targeted, safe drug delivery.
- The claims are broad but specific, aiming to differentiate through linker chemistry, targeting ligands, and nanoparticle design.
- The patent landscape shows significant overlap but also unique positioning within cleavable linker and targeted nanoparticle sectors.
- Risks include infringement and challenges over prior art; commercialization depends on regulatory validation.
5 Frequently Asked Questions
Q1: How does US 11,395,833 improve upon existing conjugation methods?
It introduces a peptide linker with a specific amino acid sequence that is enzymatically cleavable within targeted cells, enhancing drug release while reducing off-target effects.
Q2: Which therapeutic areas could most benefit from this patent?
Oncology, gene therapy, and infectious diseases where targeted delivery reduces toxicity and improves efficacy.
Q3: What are the primary competitors in this patent space?
Genentech (ADC linkers), Novartis (nanoparticle design), Pfizer (targeting ligands). Their patents cover component elements but not the specific combination claimed here.
Q4: Can modifications bypass this patent?
Altering linker sequences, ligand types, or carrier size might avoid infringement but must be carefully evaluated against prior art and patent claims.
Q5: What’s the patent's current legal status?
As of the latest update (2023), the patent is issued and enforceable, with maintenance fees paid through 2032.
References
- U.S. Patent and Trademark Office. (2023). Patent Application Publication. US Patent Application No. 17/XXXXXXXX.
